ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Supporting this idea, clinical observations demonstrate that CML patients with type 2 diabetes have enhanced levels of serum C-peptide while taking c-Abl tyrosine inhibitor [23].